US Executive Compensation Proxy SEC Filings — October 08, 2026

08-10-2026

Jaguar Health's DEF 14A proxy statement, dated October 8, 2026, sets out beneficial ownership as of September 15, 2026 for 5% holders, named executive officers and directors. Streeterville Capital LLC and Uptown Capital, LLC (both controlled by John M. Fife) hold the largest Series Q Preferred positions, while Joshua Mailman is reported at 9.99% of Common Stock. The filing references a September 2026 reverse stock split (RSS), and holdings of individual directors and officers are each below 1% of Common Stock.

• · Several 5% holders are capped by 4.99% or 9.99% beneficial ownership blockers on warrants, so reported percentages may understate potential ownership on an as-converted basis.
• · Weighted average exercise prices of director and officer options range from $137.57 to $196.62, and warrant exercise prices include $35.00, $94.50, $189.35 and $190.05.
• · The filing states that holdings were not retroactively adjusted for the September 2026 RSS, so per-share figures are on a pre-split basis except where noted.
• · Filing notes the annual report was filed April 7, 2026 and the Q2 2026 10-Q was filed August 19, 2026.

08-10-2026

Robinhood Ventures Fund I (RVI) filed a definitive DEF 14A proxy statement for its 2026 virtual annual shareholder meeting, to be held November 20, 2026, asking shareholders to elect two Trustees, Meredith Whitney (Independent) and Shiv Verma (Interested, tied to Robinhood and the Adviser), to three-year terms expiring at the 2029 annual meeting. The filing reports 27,247,215 Shares outstanding as of the September 21, 2026 record date and a one-third quorum requirement. No financial performance results are disclosed in this document, so no period-over-period comparison is available.

• · Shiv Verma is an interested nominee due to his executive roles with Robinhood Markets, Inc. and the Adviser, Robinhood Ventures DE, LLC.
• · Meredith Whitney is non-interested under the Investment Company Act of 1940, and is described as having macro and strategy-driven investment research experience.
• · Voting instructions must be received by 11:59 PM Eastern Time on November 19, 2026; Q&A submissions close November 19, 2026 at 5:00 p.m. Pacific time.
• · The Fund's annual report covers the fiscal year ended March 31, 2026, and a semi-annual report for the six months ending September 30, 2026 will be available when issued.
• · The Board unanimously recommends voting FOR the election of the nominees.

08-10-2026

TPG Mortgage Investment Trust (MITT) and Cherry Hill Mortgage Investment Corporation (CHMI) have entered into a merger agreement under which CHMI will be merged into MIT Merger Sub II, LLC, a wholly owned subsidiary of MITT, subject to approval at separate special meetings of each company's stockholders. The filing is a joint proxy statement/prospectus that solicits stockholder votes, details proxy solicitation arrangements (D.F. King for MITT at approximately $20,000; Georgeson for CHMI at approximately $55,000 plus disbursements), and provides background on both companies' business profiles. The excerpt does not include the deal consideration, exchange ratio, or financial performance comparisons, so the transaction's economic terms and any period-over-period metrics cannot be assessed from this content.

• · MIT Merger Sub II, LLC was formed on August 6, 2026, solely to effect the Company Merger and has conducted no activities beyond formation and transaction-related work.
• · MITT changed its name from AG Mortgage Investment Trust, Inc. to TPG Mortgage Investment Trust, Inc. effective December 16, 2025, and is externally managed by an affiliate of TPG.
• · CHMI became internally managed effective November 14, 2024, after terminating its management agreement with its former manager and hiring its senior management team directly.
• · CHMI commenced operations on October 9, 2013, following its initial public offering, and has elected REIT taxation beginning with its taxable year ended December 31, 2013.
• · MITT's Arc Home mortgage origination business provides exposure to mortgage banking and loan servicing rights alongside its investment portfolio.

08-10-2026

BGC Group, Inc. filed a DEF 14A proxy statement on October 8, 2026, ahead of a meeting period dated November 17, 2026. The excerpt provided is largely XBRL tagging and header metadata covering fiscal year 2025 executive compensation (Summary Compensation Table and pay-versus-performance disclosures) for named executives including Howard Lutnick, Sean Windeatt, JP Aubin, and John Abularrage. No narrative figures on compensation totals, company performance, or proposals were legible in the excerpt.

• · Filing covers executive compensation disclosures for fiscal year 2025, with comparison years 2021 through 2024 in the pay-versus-performance tables
• · Conformed period of report is November 17, 2026, indicating the associated shareholder meeting timing
• · Company business address is 499 Park Avenue, New York, NY; SEC file number 001-35591

08-10-2026

Leatt Corporation has filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders, to be held virtually on November 20, 2026 at 11:00 a.m. ET, with a record date of September 24, 2026. Stockholders will vote on electing three directors, ratifying M&K CPAS, PLLC as auditor for fiscal 2026, approving a 2026 Equity Incentive Plan, a non-binding say-on-pay vote, and a say-on-frequency vote. The filing's pay-versus-performance disclosure shows CEO Sean Macdonald's compensation actually paid rising from $231,762 in 2024 to $623,512 in 2025, while average non-PEO NEO compensation actually paid rose from $433,799 to $746,443.

• · Proposal 3 seeks stockholder approval of a new 2026 Equity Incentive Plan, which would be a material change to the company's equity compensation framework.
• · Proposal 5 asks stockholders to set the frequency of future non-binding say-on-pay votes.
• · Internet voting closes at 11:59 p.m. ET on November 19, 2026, and the company is holding a virtual-only meeting.
• · The 2025 Annual Report on Form 10-K accompanies the notice but is not part of the proxy statement.

08-10-2026

Siebert Financial Corp. (SIEB) filed its DEF 14A proxy statement dated October 8, 2026, which includes notice that the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 is available free of charge upon written request to Secretary Andrew H. Reich. The excerpt provided is limited to the closing notice and voting instructions, so no financial results, shareholder proposals, or compensation figures can be verified from this text.

• · Annual Report referenced covers fiscal year ended December 31, 2025
• · Shareholder inquiries directed to 653 Collins Avenue, Miami Beach, FL 33139, phone (310) 385-1861
• · XBRL tagging indicates compensation disclosures for PEO John J. Gebbia and non-PEO NEOs covering 2023-2025

08-10-2026

AngioDynamics, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Shareholders to be held virtually on November 17, 2026. The meeting will include the election of two Class II directors, ratification of the independent auditor, an advisory say-on-pay vote, and approval of an amendment to the 2020 Equity Incentive Plan to increase shares available for issuance. For fiscal year 2026, total GAAP revenue grew 9.5%, with the Med Tech platform growing 18.4% and the Med Device platform growing only 2.6%, partially offset by softness in Ports and other Oncology products.

• · The annual meeting will be held virtually on November 17, 2026 at 12:00 p.m. ET.
• · Record date for shareholders to vote is September 18, 2026.
• · 7 of 8 directors are independent; all board committees composed exclusively of independent directors.
• · 50% of target long-term incentive opportunity is performance-contingent and measured over three years.
• · Stock-based awards have four-year vesting to promote retention.
• · The company has a clawback policy and double trigger change-in-control provisions.
• · Med Device platform growth of 2.6% was partially offset by softness in Ports and other Oncology products.

08-10-2026

NanoViricides, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders, scheduled for November 21, 2026, at 10:00 AM EST in Stamford, CT. The meeting will include the election of three director nominees (Todd E. Rokita, Makarand Jawadekar, Brian Zucker) and ratification of EisnerAmper LLP as the independent auditor for FY 2027. The filing also sets a June 3, 2027 deadline for stockholder proposals to be included in the proxy for the 2027 annual meeting.

• · Record date for stockholders to vote is not explicitly stated in the filing excerpt, but the proxy card references a voting deadline of November 19, 2026 at 11:59 PM ET.
• · The Annual Report on Form 10-K for the year ended June 30, 2026 is available on the SEC website.
• · Stockholder proposals for the 2027 Annual Meeting must be received by June 3, 2027.
• · The meeting location is Hampton Inn & Suites Stamford, 26 Mill River Street, Stamford, CT 06902.

08-10-2026

Palomino Laboratories Inc. filed a proxy statement on October 8, 2026 for its Annual Meeting. The company seeks shareholder approval on three proposals: re-election of all three current directors (Jeffrey Shealy, Steven DenBaars, Richard Ogawa), ratification of KNAV CPA LLP as independent auditor for FY2026, and an amendment to increase the share reserve under the 2025 Equity Incentive Plan to the greater of 10 million shares or 15% of outstanding common stock. The board unanimously recommends a 'FOR' vote on all proposals.

• · Proxies may be solicited by directors, executive officers, and regular employees without additional compensation.
• · The cost of soliciting proxies will be borne by the Company.
• · Shareholders have no dissenters' rights of appraisal under Delaware General Corporation Law for any proposal.
• · The 2025 Plan was adopted in connection with the Company's reverse merger in September 2025.
• · The Plan Amendment revises Section 16(a)(i) to clarify that share reserve increases under Section 17(c) do not require a separate amendment.